Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Iguratimod in Patients With Active Primary Sjogren's Syndrome.
NCT04830644 is registered in ClinicalTrials.gov with Jiangsu Simcere Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Iguratimod in Patients With Active Primary Sjogren's Syndrome.
- Lead sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 22, 2021
- Completion date
- June 30, 2022
- Enrollment
- 144 (estimated)
- Sites
- 30
Conditions
As the registry lists them; a condition with its own page is linked.
primary sjögren syndrome